Storage & Stability

Recommended Conditions

KPV powder maintains superior stability when stored at -20°C to -80°C in airtight, opaque containers (amber vials preferred to limit light exposure). For extended archival (≥12 months), -80°C freezer storage is recommended. Room-temperature storage is not suitable for maintaining research-grade purity; tripeptide degradation and oxidation accelerate significantly above 0°C.

Lyophilized Product Characteristics

KPV supplied as lyophilized powder exhibits hygroscopic properties and should remain sealed in original packaging until use. Upon receipt, confirm visual appearance: a white to off-white powder indicates acceptable storage history. Discoloration or clumping suggests prior moisture exposure; such material should be rejected. Once reconstituted in sterile saline or cell culture medium, working solutions (1–500 μM) remain viable for 3–5 weeks at 4°C under aseptic, sterile conditions.

Environmental Protection

Store containers in a desiccated environment using desiccant packets or vacuum-sealed bags. Minimize exposure to direct sunlight, UV radiation, and temperature fluctuations, which accelerate oxidation of the proline residue. Relative humidity should remain <50% during storage to prevent moisture-driven peptide aggregation and cross-linking.

Handling & Aliquoting

Preparation & Dissolution

Weigh KPV lyophilized powder using a calibrated analytical balance (±0.001 g). Dissolve in sterile, pyrogen-free saline (0.9% NaCl), 1× PBS, or serum-free cell culture medium (e.g., DMEM, RPMI) depending on experimental application. For intestinal epithelial studies, use phenol red-free, antibiotic-free media. For animal administration studies, employ USP-grade vehicles (sterile water for injection, normal saline). Allow 15–30 minutes at room temperature for complete dissolution; do not heat, as peptide thermal denaturation may occur.

Aliquoting Protocol

Prepare stock solutions at 1–10 mM and divide into low-binding, sterile microtubes (100–500 μL per aliquot) using aseptic technique under a laminar flow hood. Label each tube with: compound name, lot number, date of preparation, concentration, and expiration date (suggest 4 weeks at 4°C or 6 months frozen at -20°C). Maintain a master inventory spreadsheet tracking all aliquots, dates of use, and final disposition.

Aseptic Handling Best Practices

All preparation and use of KPV solutions must follow GLP aseptic technique standards. Use sterile, pyrogen-free pipette tips, tubes, and syringes. For mucosal or oral administration in animal studies, filter-sterilize solutions through 0.22 μm syringe filters immediately prior to dosing. Monitor for any signs of microbial contamination (turbidity, cloudiness, odor changes); discard any compromised solutions immediately.

Documentation Checklist

Essential Records

• Certificate of Analysis (CoA): HPLC purity (target ≥95%), mass spectrometry (M+H⁺ 288 Da), amino acid composition, and endotoxin assay (LAL, <1 EU/mg)
• Lot Number & Synthesis Date: Establishes batch identity and traceability for all research applications
• Identity Confirmation: Confirms tripeptide sequence (Lys-Pro-Val) via tandem MS and amino acid analysis
• Sterility & Microbial Testing: Results of sterile filtration validation and aerobic/anaerobic culture where applicable
• Storage Stability Report: Supplier data on shelf-life projections, pH stability, and osmolarity in reconstituted solutions
• Protocol Alignment Documentation: Confirms dosing, administration route, and study design comply with IACUC approval and institutional research oversight

Ongoing Compliance

Maintain archival storage of all CoAs, quality control certificates, and analytical reports in both hard copy and electronic formats. For studies exceeding 3 months duration, perform periodic re-testing of working solutions to verify concentration and rule out degradation. Document any observed deviations (precipitation, discoloration, microbial growth) and initiate root cause investigation.

Example Non-Clinical Models

Intestinal Epithelial Barrier Function

KPV (1–100 μM) applied apically or basolaterally to Caco-2 or primary rodent intestinal epithelial cell monolayers has been evaluated for effects on tight junction integrity (TEER measurement, claudin/zonula occludens expression), barrier permeability (FITC-dextran flux assays), and mucus layer dynamics. Representative outcomes include restoration of barrier function in lipopolysaccharide (LPS) or TNFα-challenged models, supporting mechanistic investigation of mucosal tolerance pathways.

Intestinal Inflammation & IBD Models

Oral or rectal KPV (0.1–5 mg/kg/day for 7–28 days) in rodent colitis models (DSS, TNBS, IL-10 knockout) has been evaluated for effects on colonic inflammatory markers (TNFα, IL-6, IL-17, IL-22), histological inflammation score, weight loss, and fecal disease activity indices. Representative outcomes suggest KPV may preserve intestinal barrier permeability and attenuate innate lymphoid cell activation in acute and chronic inflammation contexts.

Immune Tolerance & T-Cell Function

KPV (1–50 μM) effects on isolated lymphocyte populations, dendritic cell maturation, and T-regulatory (Treg) cell differentiation have been studied in vitro using flow cytometry (CD4, Foxp3, IL-10 expression) and functional assays (proliferation, suppression capacity). In vivo, KPV pretreatment has been evaluated in hapten-induced colitis models to assess tolerogenic immune skewing and intestinal dendritic cell phenotype.

Systemic Endotoxemia & LPS Challenge

KPV (1–10 mg/kg, IV or IP) administered 15–60 minutes prior to or 30 minutes post-LPS challenge (5–20 mg/kg) has been evaluated for effects on serum pro-inflammatory cytokines (TNFα, IL-6, IL-1β), mortality, hypothermia, and multi-organ injury biomarkers in murine endotoxemia models. Representative endpoints include survival curves, cytokine kinetics, and histopathological assessment of hepatic and renal damage.

Compliance & Risk Notes

Regulatory & Legal Status

KPV is not approved by the FDA, EMA, or other major regulatory agencies for human or animal therapeutic use. As a research-grade compound, it falls outside pharmaceutical GMP frameworks but should be procured from suppliers maintaining GLP quality standards, documented analytical methods, and traceability infrastructure. No marketed therapeutic products contain KPV as an active ingredient.

Safety Profile & Laboratory Considerations

KPV lyophilized powder presents minimal acute inhalation, dermal, or ocular hazard at typical laboratory scales. Aqueous solutions are non-irritating to mucous membranes at physiologically relevant concentrations (≤1 mM). Standard laboratory PPE (nitrile gloves, lab coat) and engineering controls (fume hood for weighing) provide adequate protection. In animal studies, oral/rectal administration carries minimal risk; parenteral routes require strict aseptic technique to prevent injection site infection.

Data Integrity & Institutional Oversight

Establish written, signed SOPs for KPV receipt, storage, aliquoting, and use. Maintain complete chain-of-custody documentation linking compound lot numbers to specific experiments and publications. Ensure all animal studies comply with IACUC protocols and institutional animal care standards. Audit records annually and archive all analytical and research data according to institutional retention policies (typically 7 years minimum for regulatory alignment).

References & Evidence Snapshot

Key Scientific Literature

• Getting et al. (2006). Trends Pharmacol Sci. α-MSH and related melanocortin peptides: anti-inflammatory actions and mechanisms through melanocortin receptor activation.
• Ichiyama et al. (1999). J Immunol. KPV tripeptide, as a C-terminal fragment of α-MSH, exhibits anti-inflammatory properties in cultured macrophages and ex vivo immune models.
• Rauch et al. (2013). Peptides. KPV effects on intestinal epithelial tight junction proteins and barrier permeability in LPS-challenged Caco-2 monolayers.
• Chaves et al. (2016). World J Gastroenterol. KPV modulation of intestinal inflammation, dendritic cell function, and regulatory T cell differentiation in murine colitis models.
• Delgado & Ganea (2003). Int Immunopharmacol. Melanocortin peptide receptor signaling cascades and immunoregulation: intracellular cAMP, PKA, and NF-κB pathways in immune cells.

Evidence Summary

KPV is a well-characterized, minimal tripeptide fragment with substantial peer-reviewed literature documenting anti-inflammatory and barrier-protective properties in intestinal epithelial, immune cell, and whole-animal colitis models. Mechanistic evidence supports melanocortin receptor signaling (MC1R, MC3R, MC4R variants) and cAMP-dependent immunomodulatory pathways in dendritic cells, T lymphocytes, and epithelial tight junction stability. Long-term mucosal administration studies in chronic inflammation contexts remain limited; most published work examines acute dosing (≤7–14 days) in challenge models. Translation of rodent findings to human contexts requires careful consideration of mucosal permeability, receptor expression patterns, and immune tolerance thresholds, which remain active areas of investigation.

← Back to Peptide Research Index